AHA, AMA drop lawsuit challenge to No Surprises Act

The American Hospital Association (AHA) and the American Medical Association (AMA) have dropped their legal challenge to the interim final rule independent dispute resolution process of the No Surprises Act.

The No Surprises Act went into effect at the start of 2022 with the aim to protect patients against surprise billing, in which patients receive bills for healthcare services weeks or even months after treatment. However, changes to the rules have occurred over the last year as a result of lawsuits and adjustments by federal agencies.

Both healthcare associations challenged the law despite broad support to end surprise billing because the revised final version of the law, published August 26, favors insurers instead of aligning with Congress’ intent, they stated. 

“No patient should fear receiving a surprise medical bill. That is why the AHA and AMA strongly supported the No Surprises Act to protect patients from unexpected medical bills and keep them out of the middle of any billing disputes between providers and commercial health insurance companies,” the associations said in a statement Sept. 21. “Congress enacted the law with a balanced, patient-friendly approach, and it should be implemented that way. We have serious concerns that the August 2022 final rule departs from Congressional intent just as the September 2021 interim final rule did. Hospitals and doctors intend to make our voices heard in the courts very soon about these continued problems.”

In August 2022, the U.S. Departments of Health and Human Services, Labor and the Treasury released final rules on surprise billing, finalizing certain requirements in the July 2021 interim rules. Earlier in 2022, the U.S. District Court for the Eastern District of Texas stripped parts of the No Surprises Act, including payment determinations under the federal independent dispute resolution (IDR) process. The rules as of July 2021 protected against balance billing and out-of-network cost sharing, as well as requiring plans and issuers to disclose the qualifying payment amount (QPA) to providers. 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.